Esophageal brush cytology in cancer detection

Esophageal brush cytology is a minimally invasive method for collecting cells from the lining of the oesophagus. During endoscopy, a small brush is passed across a suspicious area, gathering loose or abnormal cells for examination under a microscope. The technique can support the assessment of dysplasia, squamous cell carcinoma and some glandular malignancies.

It is most useful when a lesion is difficult to biopsy, when a stricture limits access, or when several areas require rapid sampling. Brushings do not replace histology, but they can add valuable information to endoscopic inspection, imaging and tissue biopsy. This multidisciplinary approach reflects the type of evidence-based discussion promoted through international oesophageal disease education, including the ISDE congress discussion.

How the sampling technique works

The patient generally undergoes an upper gastrointestinal endoscopy, often with sedation. A cytology brush is moved repeatedly over the abnormal mucosa, and the collected material is transferred to glass slides or placed into a liquid-based preservation solution. The laboratory then prepares the sample, stains the cells and assesses their shape, arrangement and nuclear features.

A cytopathologist looks for enlarged or irregular nuclei, abnormal cell maturation, clusters suggestive of invasion and a background containing necrotic or inflammatory material. The report may describe benign, atypical, suspicious or malignant findings, although terminology varies between laboratories. Clear clinical details, endoscopic photographs and the exact location of the lesion help the pathologist interpret borderline changes.

Where brush cytology can add value

Brush cytology can produce a broader sample from a surface abnormality than a single forceps biopsy. This may help identify malignant cells in friable lesions, long strictures or areas where bleeding makes repeated biopsy difficult. It can also be useful when the endoscopic appearance is concerning but the initial biopsy is negative or inadequate.

The test has particular relevance in squamous cell carcinoma, which remains a major oesophageal cancer type internationally. In Australia, adenocarcinoma is also common and is frequently associated with Barrett’s oesophagus and chronic gastro-oesophageal reflux. Cytology may detect surface abnormalities, but targeted biopsies remain essential for grading dysplasia and confirming the tissue architecture needed for treatment planning.

Limits, false results and follow-up

A negative brushing does not reliably exclude cancer. Tumours can be patchy, cells may not shed readily, and a tight narrowing may prevent the brush from reaching the most abnormal area. Blood, food debris, inflammation and poor cellular preservation can also reduce diagnostic clarity. For these reasons, a suspicious endoscopic lesion usually warrants further investigation even when cytology is reassuring.

An atypical or suspicious result requires clinical correlation rather than immediate assumptions. Repeat endoscopy, deeper biopsy, endoscopic ultrasound, CT or PET imaging may be appropriate depending on the suspected diagnosis. Cytology can support an early warning, but histopathology generally provides the definitive diagnosis and information about invasion, differentiation and biomarker testing.

Patient and laboratory considerations in Australia

Australian patients may first present through general practice with progressive swallowing difficulty, painful swallowing, unexplained weight loss or persistent reflux. Referral pathways can differ between major centres such as Sydney, Melbourne, Brisbane and Perth and smaller regional or remote communities. Travel requirements and access to endoscopy can affect how quickly an abnormal cytology result is followed up.

Smoking, alcohol consumption, obesity and long-term reflux are relevant risk factors, while Barrett’s surveillance is guided by specialist assessment rather than population-wide screening. Diagnostic services may be delivered through public hospitals, private clinics or mixed referral pathways, with Medicare arrangements depending on the setting and service. Patients should receive a clear explanation of whether a brushing is an additional sample, what a preliminary result means and when tissue confirmation is expected.

Quality assurance is also important. Australian pathology services may operate under National Association of Testing Authorities accreditation, while devices and collection systems are subject to regulation by the Therapeutic Goods Administration. These frameworks support reliable processing, but they do not remove the need for adequate sampling and specialist interpretation.

Combining cytology with modern cancer assessment

The strongest diagnostic pathway combines symptoms, endoscopic appearance, brush cytology, forceps biopsy and imaging. Digital endoscopy can document subtle mucosal changes, while chromoendoscopy or narrow-band imaging may help target suspicious areas. Cytology is most valuable when it answers a defined clinical question rather than being treated as an isolated screening test.

Research and education also place cytology within a wider surgical pathway. Decisions about neoadjuvant therapy, endoscopic resection, oesophagectomy or palliation depend on tumour stage, fitness, location and patient preferences. Broader surgical learning resources, including this thoracic surgery resource, can complement disease-specific material when clinicians consider how diagnostic findings influence operative planning.

Weighing the main diagnostic options

Each test has a different purpose. Brush cytology is relatively quick and samples surface cells, whereas a forceps biopsy preserves tissue structure. Endoscopic ultrasound assesses depth and nearby lymph nodes, and cross-sectional imaging helps identify spread beyond the oesophageal wall. No single method answers every diagnostic and staging question.

For practical care, an abnormal appearance should prompt adequate sampling, accurate documentation and timely pathology review. Brush cytology can strengthen that process by revealing malignant or high-risk cellular changes, particularly when conventional biopsy is technically limited. The safest takeaway is simple: use cytology as a complementary test, and link every result to endoscopic findings, histology and a documented follow-up plan.